Evidence map›Paper›PMID 20713126›Full record

ReviewProgress in neurobiology2010

Preclinical and clinical research on inflammation after intracerebral hemorrhage.

Jian Wang

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Progress in neurobiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 368 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
368citing papers in PubMed, 1 pooled it
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04088630 early_phase1completednot on this mapstarted 2020, after this paper: background citation

Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage

TypeinterventionalSponsorWake Forest University Health SciencesRan2020 to 2024Enrolled28ConditionsIntracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, HypertensiveArmsFingolimod, Placebo, Open-label Fingolimod
NCT04200781 phase4unknown statusnot on this mapstarted 2019, after this paper: background citation

A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke

TypeinterventionalSponsorShuGuang HospitalRan2019 to 2022Enrolled464ConditionsHemorrhagic StrokeArmsGranules of Shengdi Dahuang Decoction, Placebo
3 · Its place in the literature

Who cites it

368 citing papers in PubMed, 1 synthesis or guideline pooled it, 597 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

308 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jian WangDepartment of Anesthesiology/Critical Care Medicine, The Johns Hopkins University, School of Medicine, 720 Rutland Avenue, Traylor Building 809, Baltimore, MD 21205, USA. jwang79@jhmi.edu.
Johns Hopkins University · US

Funding

Role of PGE2 receptors in the aging brain after intracerebral hemorrhageK01AG031926 · NIA · JOHNS HOPKINS UNIVERSITY · PI WANG, JIAN · 2008 to 2012
$536k
NIA NIH HHS K01 AG031926NIA NIH HHS K01AG031926
6 · The paper itself

Abstract

Intracerebral hemorrhage (ICH) is one of the most lethal stroke subtypes. Despite the high morbidity and mortality associated with ICH, its pathophysiology has not been investigated as well as that of ischemic stroke. Available evidence from preclinical and clinical studies suggests that inflammatory mechanisms are involved in the progression of ICH-induced secondary brain injury. For example, in preclinical ICH models, microglial activation has been shown to occur within 1h, much earlier than neutrophil infiltration. Recent advances in our understanding of neuroinflammatory pathways have revealed several new molecular targets, and related therapeutic strategies have been tested in preclinical ICH models. This review summarizes recent progress made in preclinical models of ICH, surveys preclinical and clinical studies of inflammatory cells (leukocytes, macrophages, microglia, and astrocytes) and inflammatory mediators (matrix metalloproteinases, nuclear factor erythroid 2-related factor 2, heme oxygenase, and iron), and highlights the emerging areas of therapeutic promise.

Indexed as

Disease Models, AnimalAnimalsAnti-Inflammatory AgentsBiomedical ResearchCerebral HemorrhageHeme Oxygenase (Decyclizing)HumansInflammationIronLeukocytesMacrophagesMatrix MetalloproteinasesNeurogliaNF-E2-Related Factor 2Anti-Inflammatory AgentsHeme Oxygenase (Decyclizing)IronMatrix MetalloproteinasesNF-E2-Related Factor 2

Identifiers

PMID20713126
PMCPMC2991407
OpenAlexW2118695506

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.